High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 343-360

  Gertz, Morie A ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Kumar, Shaji K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Age; Multiple myeloma; Renal failure; Stem cell transplantation; Survival

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; BUSULFAN; CD34 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HOLMIUM; IDARUBICIN; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THALIDOMIDE; THIOTEPA; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL MANIPULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GERIATRIC CARE; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LIVER VENOOCCLUSIVE DISEASE; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING; AUTOTRANSPLANTATION; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATIENT SELECTION; STEM CELL MOBILIZATION; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PATIENT SELECTION; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33644890183     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.343     Document Type: Review

References (123)

1. Attal M, Harousseau JL. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract. Res. Clin. Haematol. 12, 171-191 (1999).
2. Child JA, Morgan GJ, Davies FE et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875-1883 (2003).
3. Alegre A, Diaz-Mediavilla J, San-Miguel J et al. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Bone Marrow Transplant. 21, 133-140 (1998).
4. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 30, 673-679 (2002).
5. Powles R, Sirohi B, Kulkarni S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'? Bone Marrow Transplant. 30, 479-484 (2002).
6. Kumar S, Lacy MQ, Dispenzieri A et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 34, 161-167 (2004).
7. Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 23, 1267-1272 (1999).
8. Vesole DH, Crowley JJ, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group Phase II trial. J. Clin. Oncol. 17, 2173-2179 (1999).
9. Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F; Nordic Myeloma Study Group (NMSG). Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Eur. J. Haematol. 62, 271-277 (1999).
10. Lenhoff S, Hjorth M, Holmberg E et al. Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95, 7-11 (2000).
11. Segeren CM, Sonneveld P, van der Holt B et al. Dutch-Belgian Hemato-Oncology Co-operative Study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized Phase III study. Blood 101, 2144-2151 (2003).
12. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 27, 1037-1043 (2001).
13. Lahuerta JJ, Martinez-Lopez J, Serna JD et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br. J. Haematol. 109, 438-446 (2000).
14. Martinelli G, Terragna C, Zamagni E et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J. Clin. Oncol. 18, 2273-2281 (2000).
15. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 27, 1037-1043 (2001).
16. Davies FE, Forsyth PD, Rawstron AC et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br. J. Haematol. 112, 814-819 (2001).
17. Nadal E, Gine E, Blade J et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant. 33, 61-64 (2004).
18. Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br. J. Haematol. 113, 1015-1019 (2001).
19. Kouroukis CT, O'Brien BJ, Benger A et al. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk. Lymphoma 44, 29-37 (2003).
20. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin. Lab. Haematol. 25, 179-184 (2003).
21. Ferrara F, Palmieri S, Viola A et al. Out-patient-based peripheral blood stem cell transplantation for patients with multiple myeloma. Hematol. J. 5, 222-226 (2004).
22. Mishra V, Andresen S, Brinch L et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant. 35. 1149-1153 (2005).
23. Wisloff F, Gulbrandsen N, Nord E. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics 16, 329-341 (1999).
24. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 96, 2697-2702 (2000).
25. Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J, Nordic Myeloma Study Group. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur. J. Haematol. 66, 328-336 (2001).
26. Gulbrandsen N, Wisloff F, Brinch L et al. Nordic Myeloma Study Group. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med. Oncol. 18, 65-77 (2001).
27. Segeren CM, Sonneveld P, van der Holt B et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br. J. Haematol. 105, 127-130 (1999).
28. MacLennan IC, Cusick J; Medical Research Council Working Party on Leukaemia in Adults. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br. J. Cancer 52, 153-158 (1985).
29. Alberts DS, Salmon SE. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother. Rep. 59, 345-350 (1975).
30. Bennett JM, Silber R, Ezdinli E et al. Phase II study of adriamycin and bleomycin in patients with multiple myeloma. Cancer Treat. Rep. 62, 1367-1369 (1978).
31. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80, 887-890 (1992).
32. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med. 105, 8-11 (1986).
33. Anagnostopoulos A, Aleman A, Yang Y et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant. 33, 623-628 (2004).
34. Kumar S, Lacy MQ, Dispenzieri A et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bore Marrow Transplant. 34, 485-490 (2004).
35. Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17, 775-779 (2003).
36. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20, 4319-4323 (2002).
37. Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev. Anticancer Ther. 5, 759-766 (2005).
38. Goldschmidt H, Sonneveld P, Cremer FW et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann. Hematol. 82, 654-659 (2003).
39. Popat R, Oakervee HE, Curry N et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma (abstract). Blood 106 (2005).
40. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89, 826-831 (2004).
41. Cavo M, Zamagni E, Tosi P et al. Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106, 35-39. (2005).
42. Abdelkefi A, Torjman L, Ben Romdhane N et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant. 36, 193-198 (2005).
43. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant. 34, 229-234 (2004).
44. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood 106, 4050-4053 (2005).
45. Jagannath S, Durie BG, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 129, 776-783 (2005).
46. Oakervee HE, Popat R, Curry N et al. PAD combination therapy (PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 129, 755-762 (2005).
47. Jagannath S. Treatment of myeloma in patients not eligible for transplantation. Curr. Treat. Options Oncol. 6, 241-253 (2005).
48. Rajkumar SV. Novel approaches to the management of myeloma. Oncology 19, 621-625 (2005).
49. Gertz MA, Lacy MQ, Dispenzieri A, Hayman S. Current status of stem cell transplantation for multiple myeloma. Curr. Treat. Options Oncol. 6, 229-240 (2005).
50. Jerjis S, Croockewit S, Preijers F, Schaap N, De Witte T. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma. Leuk. Lymphoma 37, 551-560 (2000).
51. Kazmi MA, Ahsan G, Schey SA. The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma. Clin. Lab. Haematol. 23, 125-129 (2001).
52. + cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. Jpn J. Clin. Oncol. 32, 135-139 (2002).
53. + peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 13, 598-606 (2004).
54. Andre M, Baudoux E, Bron D et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 43, 50-57 (2003).
55. Arora M, Burns LJ, Barker JN et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol. Blood Marrow Transplant. 10, 395-404 (2004).
56. Jansen J, Thompson EM, Hanks S et al. Hematopoietic growth factor after autologous peripheral bood transplantation: comparison of G-CSF and GM-CSF. Bone Marrow Transplant. 23, 1251-1256 (1999).
57. Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L et al. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs. high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant. 25, 1141-1146 (2000).
58. Bargetzi MJ, Passweg J, Baertschi E et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 31, 99-103 (2003).
59. Straka C, Hebart H, Adler-Reichel S, Werding N, Emmerich B, Einsele H. Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma. Oncology 65(Suppl. 2), 94-98 (2003).
60. Gupta S, Zhou P, Hassoun H et al. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a Phase II trial. Bone Marrow Transplant. 35, 441-447 (2005).
61. Lerro KA, Medoff E, Wu Y et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant. 32, 1113-1117 (2003).
62. Desikan KR, Barlogie B, Jagannath S et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J. Clin. Oncol. 16, 1547-1553 (1998).
63. + cell-selected autologous peripheral blood stem cell transplantation. Int. J. Hematol. 70, 193-199 (1999).
64. Holmberg LA, Boekch M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94, 4029-4035 (1999).
65. Boccadoro M, Omede P, Dominietto A et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant. 25, 25-29 (2000).
66. +-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection. Ann Oncol. 14, 475-480 (2003).
67. Vogel W, Kopp HG, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J. Cancer Res. Clin. Oncol. 131, 214-218 (2005).
68. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J. Clin. Oncol. 19, 3771-3779 (2001).
69. Meloni G, Capria S, Trasarti S et al. High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma: a feasibility study. Bone Marrow Transplant. 26, 1045-1049 (2000).
70. Lahuerta JJ, Grande C, Blade J et al. Spanish Multiple Myeloma Group. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk. Lymphoma 43, 67-74 (2002).
71. Lahuerta JJ, Martinez-Lopez J, Grande C et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br. J. Haematol. 109, 138-147 (2000).
72. Cogle CR, Moreb JS, Leather HL et al. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am. J. Hematol. 73, 169-175 (2003).
73. Einsele H, Bamberg M, Budach W et al. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant. 32, 593-599 (2003).
74. Anagnostopoulos A, Aleman A, Ayers G et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100, 2607-2612 (2004).
75. Ria R, Falzetti F, Ballanti S et al Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol. J. 5, 118-122 (2004).
76. Toor AA, Ayers J, Strupeck J et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br. J. Haematol. 124, 769-776 (2004).
77. Donato ML, Aleman A, Champlin RE et al. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk. Lymphoma 45, 755-759 (2004).
78. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 23, 1003-1006 (1999).
79. Abraham R, Chen C, Tsang R et al. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant. 24, 1291-1297 (1999).
80. Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann. Hematol. 81, 374-377 (2002).
81. Chen CI, Abraham R, Tsang R, Crump M, Keating A, Stewart AK. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant. 27, 177-182 (2001).
82. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99, 731-735 (2002).
83. Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Br. J. Haematol. 110, 300-307 (2000).
84. Jantunen E, Kuittinen T, Nousiainen T. A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. Leuk. Lymphoma 43, 1961-1965 (2002).
85. Thieblemont C, Dumontet C, Saad H et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 30, 769-775 (2002).
86. 2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 33, 781-787 (2004).
87. Spencer A, Horvath N, Gibson J et al. Australasian Leukemia and Lymphoma Group. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 35, 971-977 (2005).
88. Giralt S, Bensinger W, Goodman M et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two Phase I/II trials. Blood 102, 2684-2691 (2003).
89. Dispenzieri A, Wiseman GA, Lacy MQ et al. A Phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19, 118-125 (2005).
90. Gertz M. Transplantation for multiple myeloma: pertinent questions. Blood 102, 3472-3475 (2003).
91. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 27, 525-529 (2001).
92. Coleman EA, Coon S, Hall-Barrow J, Richards K, Gaylor D, Stewart B. Feasibility of exercise during treatment for multiple myeloma. Cancer Nurs. 26, 410-419 (2003).
93. Harousseau JL, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev. 16, 245-253 (2002).
94. Soverini S, Cavo M, Cellini C et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 102, 1588-1594 (2004).
95. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 103, 20-32 (2004).
96. Gertz MA, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14) (q13;q32), t(4;14) (p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106, 2837-2840 (2005).
97. Terpos E, Apperley JF, Samson D et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant. 31, 163-170 (2003).
98. Krejci M, Buchler T, Hajek R et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant. 35, 159-164 (2005).
99. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98, 579-585 (2001).
100. Porrata LF, Gertz MA, Geyer SM et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 18, 1085-1092 (2004).
101. Nowakowski GS, Witzig TE, Dingli D et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106, 2267-2269 (2005).
102. Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 25, 533-539 (2000).
103. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br. J. Haematol. 114, 600-607 (2001).
104. Reece DE, Bredeson C, Perez WS et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs. ≥60 years of age. Bone Marrow Transplant. 32, 1135-1143 (2003).
105. Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104, 3052-3057 (2004).
106. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 14, 1310-1313 (2000).
107. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br. J. Haematol. 114, 822-829 (2001).
108. Lee CK, Zangari M, Barlogie B et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 33, 823-828 (2004).
109. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur. J. Haematol. 75, 27-33 (2005).
110. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93, 55-65 (1999).
111. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 103, 20-32 (2004).
112. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92, 3131-3136 (1998).
113. Gertz MA, Lacy MQ, Inwards DJ et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant 23, 221-226 (1999).
114. Attal M, Harousseau JL, Facon T et al. InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349, 2495-502 (2003). Erratum in: N. Engl. J. Med. (2004) 350, 2628.
115. Lahuerta JJ, Grande C, Martinez-Lopez J et al. Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma: results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea Phase II trial. Br. J. Haematol. 120, 296-303 (2003).
116. Horvath N, Hahn U, Joshua D et al. Long-term follow-up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach. Intern. Med. J. 34, 167-175 (2004).
117. Putkonen M, Rauhala A, Itala M, Kauppila M, Pelliniemi TT, Remes K. Double versus single autotransplantation in multiple myeloma: a single center experience of 100 patients. Haematologica 90, 562-563 (2005).
118. Sonneveld P, van der Holt B, Segeren CM et al. Intensive versus double intensive therapy in untreated multiple myeloma: update analysis of the randomized Phase III HOVON 24 study (abstract). Haematologica 90(Suppl. 1), 37-38 (2005).
119. Cavo M, Cellini C, Zamagni E et al. Update on high-dose therapy: Italian studies (abstract). Haematologica 90(Suppl. 1), 39-40 (2005).
120. 2 + TBI 12 Gy (MEL+TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: fmal clinical results of intergroup trial S9321 in the context of IFM 90 and MRC VII trials. Blood 104, (2004) (Abstract 156).
121. Stewart AK, Chen CI, Howson-Jan K et al. Results of a multicenter randomized Phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin. Cancer Res. 10, 8170-8176 (2004).
122. Fassas AB, Spencer T, Desikan R et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br. J. Haematol. 119, 164-168 (2002).
123. Chen CI, Nanji S, Prabhu A et al. Sequential, cycling maintenance therapy for post transplant multiple myeloma. Bone Marrow Transplant 37, 89-94 (2006).